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OBJECTIVE— The aim of this study was to determine the prevalence of diabetic nephrop-
athy among urban Asian-Indian type 2 diabetic subjects.
RESEARCHDESIGNANDMETHODS— Type 2 diabetic subjects (n 1,716), inclu-
sive of known diabetic subjects (KD subjects) (1,363 of 1,529; response rate 89.1%) and ran-
domly selected newly diagnosed diabetic subjects (NDD subjects) (n 353) were selected from
the Chennai Urban Rural Epidemiology Study (CURES). Microalbuminuria was estimated by
immunoturbidometric assay and diagnosed if albumin excretion was between 30 and 299g/mg
of creatinine, and overt nephropathy was diagnosed if albumin excretion was 300 g/mg of
creatinine in the presence of diabetic retinopathy, which was assessed by stereoscopic retinal
color photography.
RESULTS— The prevalence of overt nephropathy was 2.2% (95% CI 1.51–2.91). Microalbu-
minuria was present in 26.9% (24.8–28.9). Compared with the NDD subjects, KD subjects had
greater prevalence rates of both microalbuminuria with retinopathy and overt nephropathy (8.4
vs. 1.4%, P  0.001; and 2.6 vs. 0.8%, P  0.043, respectively). Logistic regression analysis
showed that A1C (odds ratio 1.325 [95% CI 1.256–1.399], P  0.001), smoking (odds ratio
1.464, P 0.011), duration of diabetes (1.023, P 0.046), systolic blood pressure (1.020, P
0.001), and diastolic blood pressure (1.016, P 0.022) were associated with microalbuminuria.
A1C (1.483, P 0.0001), duration of diabetes (1.073, P 0.003), and systolic blood pressure
(1.031, P  0.004) were associated with overt nephropathy.
CONCLUSIONS— The results of the study suggest that in urban Asian Indians, the prev-
alence of overt nephropathy and microalbuminuria was 2.2 and 26.9%, respectively. Duration of
diabetes, A1C, and systolic blood pressure were the common risk factors for overt nephropathy
and microalbuminuria.
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D iabetic nephropathy is the leadingcause of end-stage renal disease(ESRD) worldwide, and it is esti-
mated that 20% of type 2 diabetic pa-
tients reach ESRD during their lifetime
(1). Kidney disease in diabetic patients
is clinically characterized by increasing
rates of urinary albumin excretion,
start ing from normoalbuminuria,
which progresses to microalbuminuria,
macroalbuminuria, and eventually to
ESRD. Microalbuminuria is the earliest
clinically detectable stage of diabetic
kidney disease at which appropriate in-
terventions can retard, or reverse, the
progress of the disease.
According to the most recent esti-
mates published in theDiabetes Atlas 2006
(2), India has the largest number of dia-
betic patients in the world, estimated to
be 40.9 million in the year 2007 and
expected to increase to 69.9 million by
the year 2025. Type 2 diabetes in Asian
Indians differs from that in Europeans in
several aspects: the onset is at a younger
age, obesity is less common, and genetic
factors appear to be more common (3).
Some studies (4–6) conducted in migrant
Asian Indians in the U.K. and Europe
have reported increased prevalence of di-
abetic nephropathy compared with white
Caucasians. The few studies published on
the prevalence of diabetic nephropathy in
India have all been clinic based (7,8). In-
deed, the Diabetes Atlas 2006 (2) does not
list a single population-based study on di-
abetic nephropathy from South Asia. This
article reports on the first population-
based data on the prevalence of diabetic
nephropathy in India.
RESEARCH DESIGN AND
METHODS— Study subjects were re-
cruited from the Chennai Urban Rural
Epidemiology Study (CURES), con-
ducted on a representative population of
Chennai (formerly Madras) in southern
India, the fourth largest city in India with
a population of 5 million. The city of
Chennai is divided into 155 corporation
wards representing a socioeconomically
diverse group. The methodology of the
study has been published elsewhere (9).
Briefly, in phase 1 of CURES (urban com-
ponent), 26,001 individuals aged 20
years were screened for diabetes using a
systematic sampling technique from 46
corporation wards representative of the
various social tiers in Chennai. The selec-
tion criterion was taken as 20 years of age
due to younger age at onset of type 2 di-
abetes in Indians (9). Self-reported dia-
betic subjects identified in phase 1 (n 
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1,529) were classified as known diabetic
subjects (KD subjects). Fasting capillary
blood glucose was determined using a
One Touch Basic glucose meter (LifeScan,
Johnson & Johnson, Milpitas, CA) in all
subjects. Diabetes was diagnosed using
American Diabetes Association criteria
(10).
In phase 2 of CURES, all the KD
subjects (n 1,529) were invited to our
center for detailed studies on vascular
complications, and 1,363 consented for
both retinal examination and estimation
of microalbuminuria (response rate:
89.1%). In addition, 15% percent of
subjects with impaired fasting glucose
and 10% of subjects with normal fasting
glucose in phase 1 were requested to
take an oral glucose tolerance test. Thir-
ty-seven of the former group and 14 of
the latter group who were detected to
have diabetes according to World
Health Organization Consulting Group
criteria (2-h plasma glucose 11.1
mmol/l) (11) were added to the 320 ran-
domly chosen newly detected diabetic
subjects (NDD subjects) from phase 1 of
the study. Of the total 371 NDD sub-
jects, 353 consented for this study (re-
sponse rate: 95.1%). Thus, the final
study numbers were 1,716 diabetic
subjects (KD: 1,363  NDD: 353). The
institutional ethics committee approval
was obtained, and informed consent
was obtained from all study subjects.
Clinical and biochemical studies
Measurements of weight, height, and
waist circumference were obtained using
standardized techniques. The BMI was
calculated using the following formula:
weight (kg)/height (m2). Blood pressure
was recorded in the sitting position in the
right arm with a mercury sphygmoma-
nometer (Diamond Deluxe Industrial
Electronics and Products, Pune, India)
and rounded off to the nearest 2 mmHg.
Two readings were taken 5 min apart, and
the mean of the two was taken as the final
blood pressure reading.
A fasting blood sample was taken for
estimation of plasma glucose and serum
lipids using a Hitachi 912 autoanalyser
(Roche Diagnostics, Mannheim, Ger-
many). A1C was measured by the high-
performance liquid chromatography
method using the Variant machine (Bio-
Rad, Hercules, California).
Estimation of microalbuminuria
Microalbumin concentration was mea-
sured in a fasting urine sample using a
immunoturbidometric assay (Hitachi 902
autoanalyser; Roche Diagnostics). The
mean inter- and intra-assay coefficients of
variation were 3.5 and 4.2%, respectively.
Retinopathy
The ocular fundi were photographed us-
ing four-field stereo color retinal photog-
raphy (Zeiss FF 450 plus camera).
Photographs were graded by an ophthal-
mologist (R.M.). The minimum criterion
for diagnosis of diabetic retinopathy was
the presence of at least one definite mi-
croaneurysm in any field photographed.
Photographs were assessed and assigned a
retinopathy level, and the final diagnosis
for each patient was determined from the
grading of the worse eye according to the
Early Treatment Diabetic Retinopathy
Study criteria for severity of an individual
eye (12).
Definitions
Hypertension. Subjects with self-
reported hypertension and those who
had a systolic blood pressure of 140
mmHg and/or diastolic blood pressure
of 90 mmHg (13) were considered to
have hypertension.
Smoking. Individuals were classified as
nonsmokers and current smokers.
Microalbuminuria. Microalbuminuria
was diagnosed if the albumin excretion
was between 30 and 299 g/mg of creat-
inine (8). Overt nephropathy was diag-
nosed if albumin excretion was 300
g/mg of creatinine in the presence of di-
abetic retinopathy.
Statistical analysis
Data were expressed as means  SD.
Students t test or one-way ANOVA
(Tukey’s honestly significant difference
comparison) was used to compare con-
tinuous variables, and the 2 test was
used to compare proportions among
groups. Logistic regression analysis was
done using either microalbuminuria or
overt nephropathy as the dependent
variable to identify the risk factors. Sub-
jects were also categorized based on the
presence of retinopathy to study the risk
factors for albuminuria with and with-
out retinopathy. P  0.05 was consid-
ered significant. All analysis was done
using Windows-based SPSS statistical
package (version 10.0; SPSS, Chicago,
IL).
RESULTS— There were no significant
differences in the baseline values between
the 1,363 responders and the 166 nonre-
sponders among the KD subjects (re-
sponders versus nonresponders: aged
52 11 vs. 51 12 years, P 0.27; 46.3
vs. 51.7% male, P 0.20; fasting plasma
glucose 9.3  4.3 vs. 9.5  4.4 mmol/l,
P  0.43; systolic blood pressure 131 
22 vs. 130  22 mmHg, P  0.581; dia-
stolic blood pressure 78 12 vs. 77 11
mmHg, P  0.31).
The mean age of the total study pop-
ulation (n  1,716) was 51  11 years,
and 44.7% (n  744) were male sub-
jects. Of the total 1,716 diabetic sub-
jects studied, 462 (26.9% [95% CI
24.8 –28.9]) had microalbuminuria, 38
(2.2% [1.51–2.91]) had overt nephrop-
athy (i.e., macroalbuminuria with reti-
nopathy), and 53 (3.1% [3.27–3.91])
had macroalbuminuria without reti-
nopathy (Table 1). Compared with the
NDD subjects, KD subjects had greater
prevalence rates of both microalbumin-
uria with retinopathy and overt ne-
phropathy (8.4 vs. 1.4%, P  0.001;
and 2.6 vs. 0.8%, P  0.043, respec-
tively).
Table 2 presents the clinical and bio-
chemical characteristics of the study sub-
jects. Subjects with overt nephropathy






n 1,716 353 1,363
Microalbuminuria
Overall 462 (26.9) 84 (23.8) 378 (27.7) NS
With retinopathy 119 (6.9) 5 (1.4) 114 (8.4) 0.001
Without retinopathy 343 (20.0) 79 (22.4) 264 (19.4) NS
Overt nephropathy (macroalbuminuria
with retinopathy)
38 (2.2) 3 (0.8) 35 (2.6) 0.043
Macroalbuminuria without retinopathy 53 (3.1) 10 (2.8) 43 (3.2) NS
Data are n (%). NS, not significant.
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were older and had a longer duration of
diabetes (P for trend 0.0001). Systolic
and diastolic blood pressure, fasting
plasma glucose, and A1C values were
highest among the overt nephropathy
group, followed by microalbuminuric
and normoalbuminuric subjects (P for
trend 0.0001). Prevalence of hyperten-
sion was higher among subjects with mi-
croalbuminuria and overt nephropathy
compared with the normoalbuminuric
group (P  0.001). Subjects with mi-
croalbuminuria who had retinopathy had
lower BMI (23.54  3.71 vs. 25.51 
4.45 kg/m2) and waist circumference
(88 9 vs. 92 11 cm) but higher fast-
ing plasma glucose (12.1 4.3 vs. 9.6
3.6 mmol/l) and A1C values (10.6  2.0
vs. 9.2  2.2%) and longer duration of
diabetes (8 6 vs. 5 5 years) compared
with those without retinopathy. Other pa-
rameters like age and blood pressure did
not vary significantly between the study
groups.
Prevalence of microalbuminuria and
overt nephropathy was computed in rela-
tion to duration of diabetes and A1C.
There was an increase in the prevalence of
microalbuminuria with the increase in
duration of diabetes (duration of diabetes
1.0 year: 22.3%, 1–5 years: 25.7%,
6 –10 years: 33.5%, and 10 years:
30.2%; P for trend0.001). There was a
significant increase in the prevalence of
overt nephropathy with the increase in
duration of diabetes (duration of diabetes
1.0 year: 0.7%, 1–5 years: 1.1%, 6–10
years: 3.5%, and 10 years: 7.7%; P for
trend 0.001). Prevalence of both mi-
croalbuminuria (A1C 7.0%: 14.5%,
7.0–8.9%: 22.6%, 9–10.9%: 35.1%, and
10.9%: 43.4%, and overt nephropathy
(A1C 7.0%: 0.2%, 7.0–8.9%: 1.1%,
9–10.9%: 3.5%, and 10.9%: 5.5%) in-
creased with the increase in A1C levels (P
for trend 0.001).
Prevalence of microalbuminuria and
overt nephropathy was computed in rela-
tion to use of antihypertensive drugs. Of
1,716 subjects, 425 were on antihyper-
tensive medications. Prevalence of mi-
croalbuminuria and overt nephropathy
(antihypertensive drug users versus oth-
ers: microlbuminuria: 33.9 vs. 24.6%,
P  0.001; overt nephropathy: 6.6 vs.
0.8%, P  0.001) were higher in antihy-
pertensive medication users. Subjects on
antihypertensive medications were fur-
ther categorized as ACE inhibitors
(ACEIs)/angiotensin receptor blocker
(ARB) users (n  121) and others. There
was no significant difference between
these two groups with respect to mi-
croalbuminuria, whereas overt nephrop-
athy was higher in those on ACEIs/ARBs
(ACEI/ARB users vs. others: microalbu-
minuria: 35.5 vs. 33.2%, P 0.26; overt
nephropathy: 11.6 vs. 4.6%, P 0.004).
There were 23 subjects, 21 with KD
and 2 NDD, who had renal insufficiency
defined as serum creatinine levels 1.5
mg/dl. Retinopathy was present in 7 of 21
(33.3%) of KD subjects, which included
nonproliferative diabetic retinopathy in 4
and proliferative diabetic retinopathy in 3
subjects. Neither of the NDD subjects
with renal insufficiency had retinopathy.
Regression analysis revealed that
A1C (P 0.001), smoking (P 0.011),
duration of diabetes (P  0.046), sys-
tolic blood pressure (P  0.0001), and
diastolic blood pressure (P  0.022)
were associated with microalbumin-
uria. Regression analysis was carried
out after categorizing microalbumin-
uric patients with and without retinop-
athy. A1C and systolic blood pressure
were common risk factors for mi-
croalbuminuria with retinopathy (A1C
odds ratio 1.528 [95% CI 1.393–
1.676], P  0.001; systolic blood pres-
sure 1.020 [1.006 –1.035], P  0.007)
as well as without retinopathy (A1C
1.238 [1.165–1.315], P  0.001; sys-
tolic blood pressure 1.021 [1.012–
1.031], P  0.001). Smoking (1.613
[1.152–2.259], P  0.005) and dia-
stolic blood pressure (1.018 [1.002–
1.034], P  0.028) showed association
only with microalbuminuria without
retinopathy, while duration of diabetes
(1.085 [1.047–1.124], P  0.001)
showed an association only with mi-
croalbuminuria with retinopathy.
Overt nephropathy showed signifi-
cant association with A1C (P  0.0001),
duration of diabetes (P 0.003), and sys-
tolic blood pressure (P  0.004) (Table
3). None of the risk factors except dia-
stolic blood pressure showed an associa-
tion with macroalbuminuria without
retinopathy (odds ratio 1.034 [95% CI
1.002–1.068], P  0.048).
Table 4 compares the prevalence of mi-
croalbuminuria and nephropathy in differ-
ent populations (14–19). The prevalence of
overt nephropathy in Indians appears to be
lower, while that of microalbuminuria is
comparable to that reported earlier studies
in other populations.




with retinopathy) P value for trend
n 1,163 462 38
Age (years) 50  11 52  11* 57  9†‡ 0.0001
Sex (male) 503 (43.3) 225 (48.7) 16 (42.1) 0.181
Duration of diabetes (years) 4  5 5  6§ 10  6§ 0.0001
Smoking 183 (15.7) 100 (21.6) 7 (18.4) 0.044
BMI (kg/m2) 25.41  4.24 25.00  4.35 23.61  5.04* 0.004
Waist circumference (cm) 90  10 91  10 89  14 0.864
Systolic blood pressure (mmHg) 126  18 135  24§ 142  24§ 0.0001
Diastolic blood pressure (mmHg) 76  11 80  12 79  14 0.0001
Fasting plasma glucose (mmol/l) 8.2  3.6 10.2  3.9§ 12.6  4.3§ 0.0001
A1C (%) 8.2  2.1 9.5  2.3§ 11.0  2.3§ 0.0001
Hypertension (%) 40.8 59.7 86.8 0.001
Data are means SD or n (%), unless otherwise indicated. *P 0.05 vs. normal; †P 0.01 vs. normal; ‡P 0.05 vs. microalbuminuria; §P 0.001 vs. normal;
P  0.001 vs. microalbuminuria.
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CONCLUSIONS— This , to our
knowledge, is the first population-based
study from India on the prevalence of,
and risk factors for, diabetic nephropa-
thy. The main findings of this study are
that in urban Asian Indians 1) prevalence
of overt diabetic nephropathy was 2.2%
and that of microalbuminuria 26.9% and
2) risk factors for diabetic nephropathy
include A1C, duration of diabetes, and
systolic blood pressure, while for mi-
croalbuminuria smoking and diastolic
blood pressure were also risk factors.
We compared our prevalence rates
with other population-based studies on
diabetic nephropathy. Prevalence of ne-
phropathy was extremely high among
Nauruans (75% in self-reported KD
subjects and 63% in NDD subjects) (20)
and Pima Indians (47%) (21). A popu-
lation-based study in Egypt recorded a
prevalence of albuminuria of 21%
among KD subjects (22). It had been
earlier reported that migrant Indians
have a higher prevalence of diabetic ne-
phropathy compared with the host pop-
ulations (4 – 6,23). Compared with
these studies and others presented in
Table 4, our study shows a lower prev-
alence of diabetic nephropathy.
The large differences observed in
the prevalence of nephropathy among
different studies could be attributed to
the differences in study design and
methodologies adopted for defining the
disease. Many of the studies were clinic
based, and this could have introduced a
referral bias. In addition, most of these
studies have not included retinopathy
in the definition for diagnosis of dia-
betic nephropathy. The strength of our
study is that it is population based and
has included diabetic retinopathy in the
definition with the latter diagnosed us-
ing retinal color photography. These
differences in methodologies used
could probably explain the lower prev-
alence of overt nephropathy observed in
our study. However, one cannot rule
out the possibility of true ethnic differ-
ences in the prevalence of nephropathy
due to decreased susceptibility to mi-
crovascular disease in native Asian In-
dians. In support of this, in an earlier
study (24) we had reported that the
prevalence of diabetic retinopathy is
lower in Indians compared with other
ethnic groups. These findings, if con-
firmed by future studies, would be of
great interest, as Asian Indians are
known to have much higher rates of
premature coronary artery disease com-
pared with other ethnic groups (25).
There could be several explanations for
the lower prevalence of microvascular
complications noted in our studies. It is
possible that due to wide publicity of
the Diabetes Control and Complica-
tions Trial and the U.K. Prospective Di-
abetes Study results control of diabetes
is improving globally, including in In-
dia, which could have resulted in lower
rates of microvascular complications.
Second, the prevalence of hypertension
is known to be lower in native south
Asians, and this may afford a relative
protection against diabetic kidney dis-
ease (26). Finally, consequent to the
greater awareness of the nephroprotec-
tive action of ACEIs and ARBs, usage of
these drugs for preventing nephropathy
has increased. This could also affect the
prevalence rates of nephropathy com-
pared with older studies. These are,
however, purely speculative and need
to be addressed by future, preferably
longitudinal, studies.
The criteria used for the diagnosis of
Table 3—Multiple logistic regression analysis
Dependent variable and parameters Odds ratio (95% CI) P value
Overt nephropathy
Age 1.023 (0.983–1.065) 0.263
Smoking (yes  1, no  0) 1.221 (0.512–2.914) 0.652
A1C 1.483 (1.297–1.695) 0.0001
Duration of diabetes 1.073 (1.024–1.125) 0.003
Systolic blood pressure 1.031 (1.010–1.053) 0.004
Diastolic blood pressure 0.973 (0.936–1.011) 0.165
Microalbuminuria
Age 1.002 (0.990–1.015) 0.731
Smoking (yes  1, no  0) 1.464 (1.091–2.914) 0.011
A1C 1.325 (1.256–1.399) 0.0001
Duration of diabetes 1.023 (1.001–1.047) 0.046
Systolic blood pressure 1.020 (1.012–1.028) 0.0001
Diastolic blood pressure 1.016 (1.002–1.031) 0.022
Table 4—Prevalence of nephropathy and microalbuminuria in type 2 diabetes in different population-based studies
Author (reference) Place, year






Bruno et al. (14) Italy, 1996 1,574, population based 32.1% (20–200 g/min) 17.6% (200 g/min)
Gatling et al. (15) Poole, U.K., 1988 450, population based — 7.0% (300 mg/g creatinine)
Neil et al. (16) Oxford, U.K., 1993 246, population based 15% (40 mg/l) 4% (200 mg/l)
Wirta et al. (17) Finland, 1995 188, population based NDD subjects: 29%; KD subjects:
27% (30–300 mg/24 h)
NDD subjects: 4%; KD subjects:
7% (300 mg/24 h)
Collins et al. (18) Western Samoa,
1995
162, population based NDD subjects: 22.0%; KD
subjects: 17.2% (30–299 g/
ml)
NDD subjects 3.9%; KD subjects:
6.3% (300 g/ml)
Klein et al. (19) Wisconsin, 1993 798, population based 25.9% (30–299 mg/l) 16.0% (300 mg/l)
Unnikrishnan et al.
(present study)
Chennai, India, 2004 1,716, population based 26.9% (albumin excretion: 30–
299 g/mg of creatinine)
2.2% (albumin excretion 300
g/mg of creatinine in the
presence of diabetic
retinopathy)
Diabetic nephropathy in Asian Indians
2022 DIABETES CARE, VOLUME 30, NUMBER 8, AUGUST 2007
overt nephropathy in this study included
retinopathy, as it makes the diagnosis of
diabetic nephropathy more specific.
However, we compared the risk factors
for albuminuria with and without reti-
nopathy to highlight the possible differ-
ences in risk factors. Poor glycemic
control, long duration of diabetes, and
systolic blood pressure were the risk fac-
tors for overt nephropathy. This is similar
to results reported in several other studies
(1,27).
In the subset of individuals who had
macroalbuminuria without retinopathy
(possibly suggestive of nondiabetic renal
disease), diastolic blood pressure was the
only associated risk factor. Moreover, the
fact that the prevalence of this entity was
higher among the newly detected diabetic
subjects suggests that a significant pro-
portion of these individuals could have
nonspecific proteinuria/macroalbumin-
uria associated with uncontrolled hyper-
glycemia. However, some may indeed
have diabetic nephropathy, as studies
have shown that some patients in this cat-
egory have histological changes of dia-
betic nephropathy (28,29). The pre-
valence of microalbuminuria in this study
was not remarkably different from that re-
ported in other studies. For microalbu-
minuria, the risk factors were similar to
those for overt nephropathy, but smoking
and diastolic blood pressures were addi-
tional risk factors.
The major limitation of the study is
that being an epidemiological study, due
to logistic reasons, only one measure of
albuminuria was done in spot urine.
However, this may not alter the inferences
drawn, as most epidemiological studies
have only used a single measure. The
prevalence of microalbuminuria could,
however, have been lower if repeated
measurements of albumin were done, as
has been shown in clinic-based studies
(30). Another limitation is that renal bi-
opsies were not performed, as it is diffi-
cult to carry out these procedures in
population-based studies due to logistic
and ethical reasons.
This study is of importance given the
growing epidemic of diabetes in India. It
is estimated that as of the year 2007, there
are 40.9 million diabetic individuals in
India (2). The prevalence of overt ne-
phropathy in this study (i.e., 2.2%), when
translated into numbers, would imply
that 850,000 individuals in India have
overt nephropathy. Most patients with
macroproteinuria eventually reach ESRD
(1,31). The cost of a renal transplant in
India is $4,760 U.S. (Rs. 2,00,000),
which is unaffordable to the majority of
people in India (32). The absolute num-
ber of subjects with diabetic nephropathy
thus presents an economic burden to
both the individual and the society. The
large pool of microalbuminuria also sug-
gests that there could be large increases in
overt nephropathy with time, unless ag-
gressive control of diabetes and hyperten-
sion is initiated.
In conclusion, the results of this study
suggest that the prevalence of overt dia-
betic nephropathy in Asian Indians is
lower, while that of microalbuminuria is
comparable to that reported in other eth-
nic groups. Risk factors for overt ne-
phropathy are found to be poor glycemic
control, long duration of diabetes, and
systolic blood pressure, while for mi-
croalbuminuria smoking and diastolic
blood pressure were additional risk fac-
tors. There is an urgent need to launch a
national diabetes control program to
tackle the potential economic burden due
to diabetic nephropathy in India.
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